ReviewThe pharmacogenomics journal2008
Pharmacogenetic studies in depression: a proposal for methodologic guidelines.
Review in The pharmacogenomics journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Molecular psychiatry · 2010Pooled it
- Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.Journal of clinical psychopharmacology · 2010Trial
- Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.The American journal of psychiatry · 2010Trial
- Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Psychiatric services (Washington, D.C.) · 2009Trial
- Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.Molecular neuropsychiatry · 2018Article
- Role of the 5-HTTLPR and SNP Promoter Polymorphisms on Serotonin Transporter Gene Expression: a Closer Look at Genetic Architecture and In Vitro Functional Studies of Common and Uncommon Allelic Variants.Molecular neurobiology · 2016Review
- Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study.The Indian journal of medical research · 2015Article
- Positive perception of pharmacogenetic testing for psychotropic medications.Human psychopharmacology · 2014Article
- Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training.Journal of genetic counseling · 2014Article
- From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2014Review
- Clinical and molecular genetics of psychotic depression.Schizophrenia bulletin · 2013Review
- Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.Psychopharmacology · 2013Article
- Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study.Molecular psychiatry · 2013Article
- Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.CNS spectrums · 2012Article
- Gene-environment interaction in major depression and antidepressant treatment response.Current psychiatry reports · 2012Review
- Article
- Genome-wide association studies of antidepressant outcome: a brief review.Progress in neuro-psychopharmacology & biological psychiatry · 2011Review
- Pharmacogenetics of antidepressant response.Journal of psychiatry & neuroscience : JPN · 2011Review
- Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.Current opinion in pharmacology · 2011Review
- Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetic studies in mood disorders are rapidly proliferating after the initial reports linking gene variants to treatment outcomes. However, a considerable range of methodologies has been used, making it difficult to compare results across studies and limiting the representativeness of findings. Specification of sampling source (inpatients vs outpatients, primary vs tertiary settings), standardization of diagnostic systems and treatments, adequate monitoring of compliance through plasma levels, sufficient length of observation (at least 6 weeks for acute antidepressant treatments, though 3-6 months are preferable), the use of a range of response criteria and the inclusion of possible environmental confounding variables (life events, social support, temperament) are all potentially important issues when planning pharmacogenetic studies. We reviewed the state-of-the-art methodology and suggested possible guideline for future studies.
Indexed as
Identifiers
17684474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.